NR and NMN reliably raise NAD+ in people and look safe over weeks to months, but no human trial shows they slow aging or prevent disease. In the key NR trial (n = 24), 1,000 mg a day raised blood-cell NAD+ about 60% versus placebo. A 2026 systematic review of 33 human studies found health outcomes mostly mixed or null.
NAD+ precursors (nicotinamide riboside, NR, and nicotinamide mononucleotide, NMN) are among the most heavily marketed longevity supplements, alongside delivery formats like NAD+ IV therapy and NAD+ injections. The pitch is seductive: NAD+ declines with age, these compounds raise it, therefore they should slow aging. The first two links in that chain have real human evidence. The third — that raising NAD+ actually extends healthspan in people — does not. That gap is the most important thing to understand here.
Step one: do they actually get into you?
This part is genuinely established. The first human pharmacokinetic study of nicotinamide riboside gave single oral doses of 100, 300 and 1,000 mg and found dose-dependent rises in the blood NAD+ metabolome: the precursor is absorbed and converted to NAD+ as the biochemistry predicts.[1] So the foundational claim, “NR gets into your bloodstream and feeds the NAD+ pathway,” is supported by human data, not just cell-culture hope.
Step two: do they raise NAD+ and are they safe short-term?
A randomized, double-blind, placebo-controlled crossover trial in 24 healthy middle-aged and older adults (two 6-week periods) found that 1,000 mg a day of NR was well tolerated and raised NAD+ in blood cells by about 60% compared with placebo.[2]The trial also explored cardiovascular measures such as blood pressure and arterial stiffness, with suggestive but not definitive signals. The honest read: NR reliably raises the biomarker and looks safe over the studied period, but the downstream physiological benefits were exploratory, not confirmed endpoints.
NMN: one provocative trial, much hype
NMN's most-cited human study randomized 25 overweight or obese postmenopausal women with prediabetes to 250 mg a day of NMN or placebo for 10 weeks. Muscle insulin sensitivity rose 25% (±7%, p < 0.01) on NMN and did not change on placebo.[3] It is a real, peer-reviewed randomized result — but it is one small trial, in a specific population, measuring a surrogate (insulin sensitivity) rather than a clinical outcome, and it generated published scientific debate. A separate six-week randomized trial in 48 amateur runners reported improved aerobic capacity with NMN — oxygen uptake and power at both ventilatory thresholds rose more on 600 and 1,200 mg/day than on placebo, though VO2max itself did not differ between any of the groups.[4] These are interesting, but they are small, surrogate-endpoint studies — not evidence that NMN makes people live longer or healthier in any durable, demonstrated sense.
The leap the marketing makes
Here is the load-bearing distinction. Raising a biomarker (NAD+) is not the same as improving an outcome (healthspan, disease, lifespan). The human trials credibly establish that NR and NMN raise NAD+ and appear safe in the short term, and a couple of small trials show surrogate-marker improvements. None of them demonstrate that these supplements slow human aging, prevent disease, or extend life. The animal data that fuel the excitement have repeatedly failed to translate cleanly into human outcomes for other longevity compounds, and there is no reason to assume NAD+ precursors are exempt.
A 2026 PRISMA-guided systematic review puts the whole field in one frame. It included 113 intervention studies from 2010 to October 2025, 33 of them in humans (28 randomized). Oral NR and NMN consistently raised NAD-related metabolites in blood and were generally well tolerated over weeks to months, but their effects on functional, metabolic, vascular and other healthspan outcomes were heterogeneous and often null or limited to one endpoint. The authors’ verdict: clear biological activity, clinical effectiveness for anti-aging still inconclusive.[5]
The honest bottom line
The evidence tier for NAD+ precursors in humans is preliminary and surrogate-marker level. What is well-supported: NR is bioavailable, raises NAD+, and is well-tolerated short-term; NMN shows a few small surrogate-endpoint signals. What is not supported by human data: any claim about longevity, healthspan, or disease prevention. If you take these compounds, take them knowing you are betting on a plausible mechanism with a measured biomarker — not on a proven clinical benefit. Before buying, it is worth understanding what NMN costs and how the various NAD therapy options compare on price and evidence.
